Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Stubbert, Lawton J ^a,b   Smith, Jennifer M ^a,b   McKay, Bruce C ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COCKAYNE SYNDROME GROUP B TRANSCRIPTION FACTOR; PROTEIN MLH1; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERCC6 PROTEIN, HUMAN; HELICASE; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XPA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; EXCISION REPAIR; HUMAN; HUMAN CELL; HUMAN TISSUE; MISMATCH REPAIR; PROSTATE CARCINOMA; RNA INTERFERENCE; TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR; TRANSCRIPTION REGULATION; CELL STRAIN HCT116; COLORECTAL TUMOR; DNA REPAIR; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; RADIATION RESPONSE; ULTRAVIOLET RADIATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; COLORECTAL NEOPLASMS; DNA HELICASES; DNA REPAIR; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MALE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS; UP-REGULATION; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 77952074647     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-207     Document Type: Article

References (85)

1. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
2. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001, 478(1-2):1-21.
3. May A, Nairn RS, Okumoto DS, Wassermann K, Stevnsner T, Jones JC, Bohr VA. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem 1993, 268(3):1650-1657.
4. Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992, 12(9):3689-3698. 360224, 1380646.
5. Jones JC, Zhen WP, Reed E, Parker RJ, Sancar A, Bohr VA. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 1991, 266(11):7101-7107.
6. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62(17):4899-4902.
7. McKay BC, Chen F, Clarke ST, Wiggin HE, Harley LM, Ljungman M. UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1. Mutat Res 2001, 485(2):93-105.
8. Sancar A. DNA excision repair. Annu Rev Biochem 1996, 65:43-81. 10.1146/annurev.bi.65.070196.000355, 8811174.
9. Balajee AS, Bohr VA. Genomic heterogeneity of nucleotide excision repair. Gene 2000, 250(1-2):15-30. 10.1016/S0378-1119(00)00172-4, 10854775.
10. Mellon I, Spivak G, Hanawalt PC. Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 1987, 51(2):241-249. 10.1016/0092-8674(87)90151-6, 3664636.
11. Tu Y, Bates S, Pfeifer GP. The transcription-repair coupling factor CSA is required for efficient repair only during the elongation stages of RNA polymerase II transcription. Mutat Res 1998, 400(1-2):143-151.
12. Tu Y, Bates S, Pfeifer GP. Sequence-specific and domain-specific DNA repair in xeroderma pigmentosum and Cockayne syndrome cells. J Biol Chem 1997, 272(33):20747-20755. 10.1074/jbc.272.33.20747, 9252397.
13. Cleaver JE. Ultraviolet photobiology: its early roots and insights into DNA repair. DNA Repair (Amst) 2002, 1(11):977-979. 10.1016/S1568-7864(02)00162-3, 12531025.
14. van Hoffen A, Natarajan AT, Mayne LV, van Zeeland AA, Mullenders LH, Venema J. Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells. Nucleic Acids Res 1993, 21(25):5890-5895. 10.1093/nar/21.25.5890, 310470, 8290349.
15. Venema J, van Hoffen A, Karcagi V, Natarajan AT, van Zeeland AA, Mullenders LH. Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol Cell Biol 1991, 11(8):4128-4134. 361228, 1649389.
16. Andera L, Wasylyk B. Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Med 1997, 3(12):852-863. 2230284, 9440118.
17. McKay BC, Becerril C, Ljungman M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001, 20(46):6805-6808. 10.1038/sj.onc.1204901, 11709715.
18. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999, 18(3):583-592. 10.1038/sj.onc.1202356, 9989808.
19. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G, Benard J. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996, 68(1):67-74. 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3, 8895543.
20. Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Cell Growth Differ 1999, 10(7):473-478.
21. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56(3):556-562.
22. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998, 4(1):1-6.
23. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002, 511(2):145-178. 10.1016/S1383-5742(02)00009-1, 12052432.
24. Pani E, Stojic L, El-Shemerly M, Jiricny J, Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 2007, 6(14):1796-1802.
25. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004, 3(8-9):1091-1101. 10.1016/j.dnarep.2004.06.006, 15279797.
26. Young LC, Thulien KJ, Campbell MR, Tron VA, Andrew SE. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study. Carcinogenesis 2004, 25(10):1821-1827. 10.1093/carcin/bgh191, 15166087.
27. Peters AC, Young LC, Maeda T, Tron VA, Andrew SE. Mammalian DNA mismatch repair protects cells from UVB-induced DNA damage by facilitating apoptosis and p53 activation. DNA Repair (Amst) 2003, 2(4):427-435. 10.1016/S1568-7864(03)00003-X, 12606123.
28. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994, 54(16):4308-4312.
29. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282(5393):1497-1501. 10.1126/science.282.5393.1497, 9822382.
30. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997, 78(Pt 7):1653-1661.
31. McKay BC, Rainbow AJ. Heat-shock enhanced reactivation of a UV-damaged reporter gene in human cells involves the transcription coupled DNA repair pathway. Mutat Res 1996, 363(2):125-135.
32. Lee DF, Drouin R, Pitsikas P, Rainbow AJ. Detection of an involvement of the human mismatch repair genes hMLH1 and hMSH2 in nucleotide excision repair is dependent on UVC fluence to cells. Cancer Res 2004, 64(11):3865-3870. 10.1158/0008-5472.CAN-03-3193, 15172995.
33. McKay BC, Chen F, Perumalswami CR, Zhang F, Ljungman M. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 2000, 11(8):2543-2551. 14938, 10930452.
34. Sauerbier W, Hercules K. Gene and transcription unit mapping by radiation effects. Annu Rev Genet 1978, 12:329-363. 10.1146/annurev.ge.12.120178.001553, 371526.
35. Protic-Sabljic M, Kraemer KH. One pyrimidine dimer inactivates expression of a transfected gene in xeroderma pigmentosum cells. Proc Natl Acad Sci USA 1985, 82(19):6622-6626. 10.1073/pnas.82.19.6622, 391262, 2995975.
36. Francis MA, Rainbow AJ. UV-enhanced reactivation of a UV-damaged reporter gene suggests transcription-coupled repair is UV-inducible in human cells. Carcinogenesis 1999, 20(1):19-26. 10.1093/carcin/20.1.19, 9934845.
37. Boszko IP, Rainbow AJ. Removal of UV photoproducts from an adenovirus-encoded reporter gene following infection of unirradiated and UV-irradiated human fibroblasts. Somat Cell Mol Genet 1999, 25(5-6):301-315. 10.1023/A:1019916415806, 15328909.
38. Rainbow AJ, McKay BC, Francis MA. Recombinant adenoviruses as expression vectors and as probes for DNA repair in human cells. Gene Ther Mol Biol 2000, 5:87-100.
39. Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001, 285(2):409-413. 10.1006/bbrc.2001.5187, 11444857.
40. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001, 61(10):4112-4121.
41. McKay BC, Francis MA, Rainbow AJ. Wildtype p53 is required for heat shock and ultraviolet light enhanced repair of a UV-damaged reporter gene. Carcinogenesis 1997, 18(2):245-249. 10.1093/carcin/18.2.245, 9054614.
42. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408(6810):307-310. 10.1038/35042675, 11099028.
43. van Oosterwijk MF, Versteeg A, Filon R, van Zeeland AA, Mullenders LH. The sensitivity of Cockayne's syndrome cells to DNA-damaging agents is not due to defective transcription-coupled repair of active genes. Mol Cell Biol 1996, 16(8):4436-4444. 231442, 8754844.
44. Proietti-De-Santis L, Drane P, Egly JM. Cockayne syndrome B protein regulates the transcriptional program after UV irradiation. Embo J 2006, 25(9):1915-1923. 10.1038/sj.emboj.7601071, 1456931, 16601682.
45. Dianov GL, Houle JF, Iyer N, Bohr VA, Friedberg EC. Reduced RNA polymerase II transcription in extracts of cockayne syndrome and xeroderma pigmentosum/Cockayne syndrome cells. Nucleic Acids Res 1997, 25(18):3636-3642. 10.1093/nar/25.18.3636, 146943, 9278484.
46. Friedberg EC, Aguilera A, Gellert M, Hanawalt PC, Hays JB, Lehmann AR, Lindahl T, Lowndes N, Sarasin A, Wood RD. DNA repair: from molecular mechanism to human disease. DNA Repair (Amst) 2006, 5(8):986-996. 10.1016/j.dnarep.2006.05.005, 16955546.
47. McKay BC, Ljungman M. Role for p53 in the recovery of transcription and protection against apoptosis induced by ultraviolet light. Neoplasia 1999, 1(3):276-284. 10.1038/sj.neo.7900028, 1508081, 10935482.
48. McKay BC, Ljungman M, Rainbow AJ. Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 1998, 17(5):545-555. 10.1038/sj.onc.1201963, 9704920.
49. Queille S, Drougard C, Sarasin A, Daya-Grosjean L. Effects of XPD mutations on ultraviolet-induced apoptosis in relation to skin cancer-proneness in repair-deficient syndromes. J Invest Dermatol 2001, 117(5):1162-1170. 10.1046/j.0022-202x.2001.01533.x, 11710928.
50. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 1996, 13(4):823-831.
51. Brash DE, Wikonkal NM, Remenyik E, Horst GT, Friedberg EC, Cheo DL, van Steeg H, Westerman A, van Kranen HJ. The DNA damage signal for Mdm2 regulation, Trp53 induction, and sunburn cell formation in vivo originates from actively transcribed genes. J Invest Dermatol 2001, 117(5):1234-1240. 10.1046/j.0022-202x.2001.01554.x, 11710938.
52. de Waard H, Sonneveld E, de Wit J, Esveldt-van Lange R, Hoeijmakers JH, Vrieling H, Horst GT. Cell-type-specific consequences of nucleotide excision repair deficiencies: Embryonic stem cells versus fibroblasts. DNA Repair (Amst) 2008, 7(10):1659-1669. 10.1016/j.dnarep.2008.06.009, 18634906.
53. Garssen J, van Steeg H, de Gruijl F, de Boer J, Horst GT, van Kranen H, van Loveren H, van Dijk M, Fluitman A, Weeda G, et al. Transcription-coupled and global genome repair differentially influence UV-B-induced acute skin effects and systemic immunosuppression. J Immunol 2000, 164(12):6199-6205.
54. McKay BC, Becerril C, Spronck JC, Ljungman M. Ultraviolet light-induced apoptosis is associated with S-phase in primary human fibroblasts. DNA Repair (Amst) 2002, 1(10):811-820. 10.1016/S1568-7864(02)00109-X, 12531028.
55. Clement V, Dunand-Sauthier I, Clarkson SG. Suppression of UV-induced apoptosis by the human DNA repair protein XPG. Cell Death Differ 2006, 13(3):478-488. 10.1038/sj.cdd.4401764, 16167068.
56. Fousteri M, Mullenders LH. Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res 2008, 18(1):73-84. 10.1038/cr.2008.6, 18166977.
57. Fousteri M, Vermeulen W, van Zeeland AA, Mullenders LH. Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. Mol Cell 2006, 23(4):471-482. 10.1016/j.molcel.2006.06.029, 16916636.
58. Fousteri M, van Hoffen A, Vargova H, Mullenders LH. Repair of DNA lesions in chromosomal DNA impact of chromatin structure and Cockayne syndrome proteins. DNA Repair (Amst) 2005, 4(8):919-925. 10.1016/j.dnarep.2005.04.011, 15961352.
59. Lu Y, Lian H, Sharma P, Schreiber-Agus N, Russell RG, Chin L, Horst GT, Bregman DB. Disruption of the Cockayne syndrome B gene impairs spontaneous tumorigenesis in cancer-predisposed Ink4a/ARF knockout mice. Mol Cell Biol 2001, 21(5):1810-1818. 10.1128/MCB.21.5.1810-1818.2001, 86742, 11238917.
60. Liu F, Yu ZJ, Sui JL, Bai B, Zhou PK. siRNA-mediated silencing of Cockayne Cyndrome group B gene potentiates radiation-induced apoptosis and antiproliferative effect in HeLa cells. Chin Med J (Engl) 2006, 119(9):731-739.
61. Lu Y, Mani S, Kandimalla ER, Yu D, Agrawal S, States JC, Bregman DB. The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International journal of oncology 2001, 19(6):1089-1097.
62. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478(1-2):23-43.
63. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003, 4(6):889-901. 10.1517/14656566.4.6.889, 12783586.
64. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279. 10.1038/sj.onc.1206933, 14576837.
65. Gonzalez-Martin A. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 2005, 15(Suppl 3):241-246. 10.1111/j.1525-1438.2005.00436.x, 16343239.
66. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4(4):307-320. 10.1038/nrd1691, 15789122.
67. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63(1):12-31. 10.1016/j.critrevonc.2007.02.001, 17336087.
68. Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008, 110(3 Suppl 2):S67-71. 10.1016/j.ygyno.2008.04.024, 18533239.
69. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009, 112(1):275-281. 10.1016/j.ygyno.2008.09.034, 18977023.
70. Chao CC. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells. Eur J Pharmacol 1994, 268(3):347-355. 10.1016/0922-4106(94)90059-0, 7805758.
71. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20(10):435-439. 10.1016/S0968-0004(00)89095-7, 8533159.
72. Petersen LN, Mamenta EL, Stevnsner T, Chaney SG, Bohr VA. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis 1996, 17(12):2597-2602. 10.1093/carcin/17.12.2597, 9006094.
73. Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 1998, 34(11):1783-1788. 10.1016/S0959-8049(98)00190-7, 9893669.
74. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000, 60(9):1305-1313. 10.1016/S0006-2952(00)00441-X, 11008124.
75. Lupi M, Matera G, Natoli C, Colombo V, Ubezio P. The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 2007, 6(8):943-950.
76. Bhana S, Lloyd DR. The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis 2008, 23(1):43-50. 10.1093/mutage/gem041, 18003626.
77. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008, 7(12):979-987. 10.1038/nrd2656, 19043449.
78. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127(3):978-983. 10.1378/chest.127.3.978, 15764785.
79. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007, 7(3):261-268. 10.1586/14737159.7.3.261, 17489733.
80. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007, 13(4):284-289. 10.1097/MCP.0b013e32816b5c63, 17534174.
81. Ceppi P, Longo M, Volante M, Novello S, Cappia S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M, et al. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 2008, 3(6):583-589. 10.1097/JTO.0b013e3181734f24, 18520795.
82. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008, 14(13):4225-4231. 10.1158/1078-0432.CCR-07-4848, 18594004.
83. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007, 13(13):3855-3859. 10.1158/1078-0432.CCR-07-0252, 17606717.
84. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528. 10.1093/annonc/mdl435, 17229776.
85. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110(3):352-361. 10.1002/ijc.20134, 15095299.